156 related articles for article (PubMed ID: 17923874)
1. Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer.
Kato T; Steers G; Campo L; Roberts H; Leek RD; Turley H; Kimura T; Kameoka S; Nishikawa T; Kobayashi M; Harris AL; Gatter KC; Pezzella F
Br J Cancer; 2007 Nov; 97(9):1277-86. PubMed ID: 17923874
[TBL] [Abstract][Full Text] [Related]
2. Microvessel density and p53 overexpression in young women with breast cancer: a case-control study.
Kalfon B; Fineberg S; Gu Y; Anand K; Dalal A ; Jones J; Sparano JA
Clin Breast Cancer; 2001 Apr; 2(1):67-72. PubMed ID: 11899385
[TBL] [Abstract][Full Text] [Related]
3. Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer.
Kato T; Pezzella F; Steers G; Campo L; Leek RD; Turley H; Kameoka S; Nishikawa T; Harris AL; Gatter KC; Fox S
Int J Clin Exp Pathol; 2014; 7(11):7967-78. PubMed ID: 25550840
[TBL] [Abstract][Full Text] [Related]
4. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer.
Jang KS; Han HX; Paik SS; Brown PH; Kong G
Cancer Lett; 2006 Dec; 244(2):203-10. PubMed ID: 16469432
[TBL] [Abstract][Full Text] [Related]
5. The influence of young age on outcome in early stage breast cancer.
Fowble BL; Schultz DJ; Overmoyer B; Solin LJ; Fox K; Jardines L; Orel S; Glick JH
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):23-33. PubMed ID: 8083119
[TBL] [Abstract][Full Text] [Related]
6. Tumor Angiogenesis in Breast Cancer: Pericytes and Maturation Does Not Correlate With Lymph Node Metastasis and Molecular Subtypes.
Shrivastav S; Bal A; Singh G; Joshi K
Clin Breast Cancer; 2016 Apr; 16(2):131-8. PubMed ID: 26452314
[TBL] [Abstract][Full Text] [Related]
7. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse.
Giatromanolaki A; Koukourakis MI; Kakolyris S; Mavroudis D; Kouroussis C; Mavroudi C; Perraki M; Sivridis E; Georgoulias V
Int J Cancer; 2004 Feb; 108(4):620-7. PubMed ID: 14696130
[TBL] [Abstract][Full Text] [Related]
8. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan.
Sawaki M; Yamada A; Kumamaru H; Miyata H; Nakayama K; Shimizu C; Miyashita M; Honma N; Taira N; Saji S
Breast Cancer; 2021 Jan; 28(1):1-8. PubMed ID: 33219915
[TBL] [Abstract][Full Text] [Related]
11. Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count.
Dhakal HP; Bassarova A; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Giercksky KE; Nesland JM
Histol Histopathol; 2009 Aug; 24(8):1049-59. PubMed ID: 19554512
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
13. Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma.
Yildiz E; Ayan S; Goze F; Gokce G; Gultekin EY
BJU Int; 2008 Mar; 101(6):758-64. PubMed ID: 18070177
[TBL] [Abstract][Full Text] [Related]
14. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
15. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging.
Li Y; Wei X; Zhang S; Zhang J
Tumour Biol; 2015 Nov; 36(11):8755-60. PubMed ID: 26052072
[TBL] [Abstract][Full Text] [Related]
17. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
19. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
Chen J; Wu X; Christos PJ; Formenti S; Nagar H
Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
